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Abstract
Background: The incidence of meningeal carcinomatosis appears to be higher than in the past due to advances in
neuro-imaging diagnostic techniques and improvements in cancer survival. Among solid tumors, breast cancer is
the cancer most commonly associated with meningeal carcinomatosis, with an incidence rate of between 0.8 and
16 %. Aim of this study has been i) to evaluate the incidence of meningeal carcinomatosis in a continuous breast
cancer unselected series treated in a dedicated Breast Unit and ii) to define the clinico-pathological and molecular
parameters associated with meningeal carcinomatosis development.
Methods: A retrospective series of 1915 consecutive patients surgically treated for breast cancer between
1998 and 2010 was collected. Clinico-pathological data were recorded from medical charts and pathological
reports, including the date of development of symptomatic meningeal carcinomatosis. Meningeal carcinomatosis
incidence was determined at both 5- and 10-year follow-ups.
Results: Three patients in the first 5 years of follow-up and six patients in 10 years of follow-up developed meningeal
carcinomatosis. An incidence rate of 5.44 per 10,000 patients (95 % CI: 1.75–16.9) was observed, with a 5-year risk of
0.3 %. At 10-year follow up, the rate increased to 7.55 per 10,000 patients (95 % CI: 3.39–16.8). In a univariate analysis,
young age, tumor size larger than 15 mm, histological grade 3, more than three metastatic lymph nodes,
negative estrogen receptor, positive HER2 and high proliferative index were significantly associated with
meningeal carcinomatosis development.
Conclusions: In an unselected breast cancer population, meningeal carcinomatosis is a rare event that is
associated with adverse prognostic factors. Meningeal carcinomatosis incidence is overestimated when
recorded in biased/high-risk selected breast cancer patients and should not be considered to accurately
reflect the overall breast cancer population.
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Background
Meningeal carcinomatosis (MC) is caused by the spread
of cancer cells to the leptomeninges and by their dissem-
ination within the cerebrospinal fluid (CSF). MC has
been reported to occur in 5–10 % of all solid tumors,
mainly in breast cancer (BC), lung cancer and malignant
melanoma in adult patients [1, 2]. In particular, MC rep-
resents a well-known complication in BC [3–5]; in re-
cent years, its occurrence has increased in this patient
setting, mainly due to advances in neuro-imaging tech-
niques and to remarkable improvements in BC survival.
However, to date, few studies have described the true in-
cidence of MC in BC patients, and the results have
proved controversial. In fact, the reported estimates of
MC occurrence vary considerably, ranging from 0.8 to
6.6 % in clinical reports to 2.6–16 % in autopsy series
[6–14]. Patients with MC clinically present with subtle
and heterogeneous signs and symptoms that depend on
the anatomical site involved (cerebral hemispheres, cra-
nial nerves, and/or spinal cord) [5, 15–17]. Diagnosis is
based on cytological CSF examination and/or magnetic
resonance imaging (MRI); these tests reportedly ex-
hibit a sensitivity ranging from 45 to 80 % for CSF
examination and from 20 to 91 % for MRI [5, 18].
Currently, therapeutic strategies include radiotherapy
and intrathecal or systemic chemotherapy; however,
the results remain poor because late diagnosis usually
leads to non-eligibility of patients for treatment and
to the delivery of palliative care only [19]. An earlier
MC diagnosis could also improve the quality of life of
BC patients who sometimes rapidly progress and need
of institutional/hospital care. In fact, survival ranges
from 4 to 6 weeks from diagnosis in untreated pa-
tients to 6 months when patients are immediately
subjected to aggressive treatment [20, 21]. Longer
survival is reported in only a few cases (13 % at 1 year
and 6 % at 2 years) [16].
Few data are available that focus on the association of
MC with peculiar clinico-morphological-molecular fea-
tures in BC patients, and no studies has effectively pin-
pointed specific predictors of MC development. The
most common parameters that have been identified to
date are: young age, ≥4 metastatic lymph nodes, high
histological tumor grade, HER2-positive status and triple
negative immune-phenotype [10, 22–26]. Recently, a
significant association with lobular histological type,
estrogen receptor (ER) and progesterone receptor (PR)-
negative status have been highlighted, as well as the
presence of metastases at diagnosis [27].
In this context, the aim of this study is twofold: (1)
to estimate the incidence of MC in a large cohort of
consecutive and unselected BC patients who were
treated in the same Breast Unit and (2) to define
which clinico-pathological and molecular parameters,
if any, are significantly associated with MC develop-
ment in order to identify patients at high risk at an
earlier stage.
Methods
Cohort definition and follow-up procedures
Our initial cohort included a consecutive series of BC
cases comprising the entire population of 2017 patients
who underwent surgery at the Città della Salute e della
Scienza of Turin between 1998 and 2010.
For all patients, follow-up data were retrieved from
the oncologists’ clinical records, and the last visit re-
corded in the cohort was registered on November
21st, 2013.
The study was submitted to and approved by the Ethic
Institutional Review Board for “Biobanking and use of
human tissues for experimental studies” of the Pathology
Service of the Azienda Ospedaliera Città della Salute e
della Scienza di Torino, Torino, Italy. The project pro-
vided a verbal and not written informed consent from
the patients due to the retrospective approach of the
study, which did not impact on their treatment. All the
cases were anonymously recorded. The Institutional
Review Board approved this consent procedure.
To accurately estimate the MC incidence rate, the
starting date for the analyses was set at January 1st,
2005, when MC started to be systematically recorded in
the Department of Neuro-Oncology of our Hospital in
BC population. Therefore, even though the follow up
started at the time of surgery, just in the subgroup of pa-
tients who underwent surgery before the first of January
2005, this date was considered as the initial period of
observation. The follow up ended at the last visit or
at MC diagnosis. Consequently, from the initial co-
hort of 2017 patients, we excluded 50 patients with-
out any follow up data (lost) and 52 patients whose
follow up ended before the first of January 2005 (be-
cause MC was never investigated in this subgroup of
patients). Therefore, 1915 patients were considered in
further analyses (Fig. 1).
To enhance the study validity, we restricted the main
analysis to the first 5 years of follow up after surgery, be-
cause most of the patients regularly participated in the
scheduled visits during this initial period, with very lim-
ited loss during follow up. For this analysis, which was
limited to the first 5 years of follow up, we excluded 122
additional patients who underwent surgery more than
5 years before the 1st of January, 2005, even though they
were still in follow up at this time. Therefore, the
final analysis, in which MC incidence rate was esti-
mated during the first 5 years of follow up, included
1793 patients (Fig. 1).
As an additional study group, we considered the entire
population of 1915 patients in an extended 10-year
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follow up (Fig. 1); in this analysis, MC incidence esti-
mates are based on a larger number of events but are
potentially biased due to lower compliance at the sched-
uled follow-up visits from 5 to 10 years after surgery.
Further extension of the follow-up up to 15 years would
introduce even greater bias, as all patients with no com-
plications are referred to their general practitioner
10 years after BC diagnosis. Only patients with compli-
cations or disease recurrence (including MC) are still
followed by the Breast Unit at the hospital.
Clinical and pathological features
For each case, clinical, morphological, immunohisto-
chemical and molecular data were collected. MC was
suspected in patients upon initial neurological symptoms
that are suggestive of meningeal involvement (i.e., head-
ache, cranial nerve palsy, back pain, radicular pain, leg
weakness, etc.). Clinical diagnoses were confirmed based
on positive abnormal brain or spinal cord MRI and/or
positive CSF cytology.
Statistical analysis
All statistical analyses were conducted using the soft-
ware STATA 11. We first estimated the incidence rate of
MC, including 95 % confidence intervals (CI), over the
first 5 years or the first 10 years of follow up after sur-
gery for BC. The cumulative risks of MC over 5-year
and 10-year after diagnosis of BC were estimated using
Kaplan-Meier analysis.
In addition, despite the limited number of MC cases,
the clinical, morphological and molecular characteristics
of the case series were studied to determine whether any
feature of the primary tumor was predictive of higher
MC risk. Several a priori selected variables, including
age, type of surgery, grading, lymph node involvement,
tumor size, vascular invasion, ER and PR status, Ki-67
immunostaining and HER2 expression, were considered.
Variables were categorized according to the literature
and international guidelines [28–32]. Due to the very
limited number of events, only univariate analyses were
conducted.
Results
The 1915 BC patients were women aged 22–93 (mean
age 61.2 years) and included 338 patients (17.6 %) youn-
ger than 50 years. Clinical and morphological data re-
garding these women are reported in Table 1, column A.
Overall, we identified nine cases of MC out of 1915
BC patients. Three out of nine patients developed lepto-
meningeal involvement more than 10 years after their
primary BC surgery and were therefore excluded from
the analyses. The clinico-pathological features of the 6
patients with MC included in this study are summarized
in Table 1, column B.
Incidence and risk of MC
The median follow up period for the 1793 patients in-
cluded in the analyses that were limited to the first
5 years of follow up was 4.78 years, and 47 % of the
patients were followed up for the full 5 years. When ana-
lyses were prolonged until 10 years of follow up (1915
patients), the median follow up period was slightly in-
creased to 5.03 years, and only 7 % of the patients were
followed up for the full 10-year period.
In the first 5 years of follow up, three patients devel-
oped MC, corresponding to a rate of 5.44 per 10,000
patients per year (95 % CI: 1.75–16.9) and an overall 5-
year risk of 0.3 % (95 % CI: 0.1–0.8) (Table 2, column
A). Extending the period of observation to 10 years of
follow up revealed a rate of 7.55 per 10,000 patients per
year (0.6 % 10-year risk, 95 % CI: 0.3–1.4), based on six
MC patients.
Clinico-pathological features and MC development
Among the 6 patients who developed MC, the median
age at time of BC diagnosis was 39.5 years (range, 32 to
49 years) and all patients showed a tumor size larger
than 15 mm. The most common histological subtype
was infiltrative ductal carcinoma (5/6 cases) with a high
(66.7 %) or intermediate (33.3 %) histological tumor
grade. Three of the six patients (50 %) had more than
three axillary lymph node metastases. ER and PR immu-
nostain was positive in 50 % of cases; in 66.7 % of BC
Fig. 1 Patient series included in the study
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cases, Ki67 was higher than 20 %. HER2 status was posi-
tive in 3/6 cases (50 %). Vascular invasion was present in
five cases (83.3 %).
Univariate analysis showed that younger age, tumor
size more than 15 mm, high histological tumor grade
(G3), ER-negative status, HER2-positive status and high
proliferative index were associated with MC develop-
ment, considering the first 5 years of follow up (Table 2,
column A). These associations were replicated in the
analyses based on 10 years of follow-up extended
Table 1 Clinico-pathological and molecular features of 1915
patients who were included in our analyses and underwent
surgery between 1998 and 2010 (column A), highlighting the
features of 6 patients with MC occurring during the first 10 years
of follow up and considered in the analyses (column B)
Collected parameters Column A Column B
Patients
n = 1915 (%)
Patients with
MC n = 6 (%)
Age at diagnosis of BC
- <50 years 338 (17.6 %) 6 (100 %)
- ≥50 years 1577 (82.4 %) 0
Treatment
- T (umorectomy) 1400 (73.1 %) 2 (33.3 %)
- M (astectomy) 515 (26.9 %) 4 (66.7 %)
Histological type
- IDC 1154 (60.3 %) 5 (83.3 %)
- ILI 348 (18.2 %) 0
- Mixed IDC-ILI 146 (7.6 %) 1 (16.7 %)
- Others 267 (13.9 %) 0
Histological grade
- G1 564 (29.5 %) 0
- G2 908 (47.4 %) 2 (33.3 %)
- G3 435 (22.7 %) 4 (66.7 %)
- Not available 8 (0.4 %) 0
Tumor size
- ≤ 15 mm 1019 (53.2 %) 0
- > 15 mm 890 (46.5 %) 6 (100 %)
- Not available 6 (0.3 %) 0
Vascular invasion
- No 1271 (66.4 %) 1 (16.7 %)
- Yes 626 (32.7 %) 5 (83.3 %)
- Not available 18 (0.9 %) 0
pT stage
- pT1 1342 (70.1 %) 1 (16.7 %)
- pT2 493 (25.7 %) 5 (83.3 %)
- pT3-4 76 (4 %) 0
- Not available 4 (0.2 %) 0
pN stage
- Negative (including ITC/
micrometastasis)/pN0
1335 (69.7 %) 1 (16.7 %)
- from 1 to 3 nodes positive/pN1 338 (17.7 %) 2 (33.3 %)
- >3 nodes positive/pN2-pN3 167 (8.7 %) 3 (50 %)
- Not available 75 (3.9 %) 0
cM stage at diagnosis
cM0 1889 (98.6 %) 4 (66.7 %)
cM1 26 (1.4 %) 2 (33.3 %)
Bone metastases
- no 1818 (94.9 %) 3 (50 %)
Table 1 Clinico-pathological and molecular features of 1915
patients who were included in our analyses and underwent
surgery between 1998 and 2010 (column A), highlighting the
features of 6 patients with MC occurring during the first 10 years
of follow up and considered in the analyses (column B)
(Continued)
- yes 97 (5.1 %) 3 (50 %)
Brain metastases
- no 1898 (99.1 %) 1 (16.7 %)
- yes 17 (0.9 %) 5 (83.3 %)
Metastases in other site, NAS
- no 1686 (88 %) 0
- yes 229 (12 %) 6 (100 %)
ER status
Negative 190 (9.9 %) 3 (50 %)
Positive 1693 (88.4 %) 3 (50 %)
Not available 32 (1.7 %) 0
PR status
- Negative 256 (13.4 %) 2 (33.3 %)
- Positive 1365 (71.3 %) 3 (50 %)
- Not available 294 (15.4 %) 1 (16.7 %)
Ki67
- <20 % 1103 (57.6 %) 2 (33.3 %)
- ≥20 % 741 (38.7 %) 4 (66.7 %)
- Not available 71 (3.7 %) 0
HER2
- negative 1662 (86.8 %) 3 (50 %)
- positive 151 (7.9 %) 3 (50 %)
- Not available 101 (5.3 %) 0
Neoadjuvant chemotherapy
- No 1836 (95.9 %) 3 (50 %)
- Yes 79 (4.1 %) 3 (50 %)
Adjuvant treatment
- Chemotherapy 722 (37.7 %) 4 (66.7 %)
- Radiotherapy 1352 (70.6 %) 1 (16.7 %)
- Hormone therapy 1520 (79.4 %) 2 (33.3 %)
IDC Infiltrating ductal carcinoma, ILC Infiltrating lobular carcinoma, G
histological tumor grade [28], ITC isolated tumor cells
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Table 2 Rate of breast cancer-related meningeal carcinomatosis, 5 years (column A) and 10 years (column B) after surgery
Column A: 5-year follow upa Column B: 10-year follow upb
MC events Patients Person-years Rate (per 10.000) MC events Patients Person-years Rate (per 10.000)
Patients 3 1793 5518 5.44 (1.75–16.9) 6 1915 7947 7.55 (3.39–16.8)
Age at diagnosis
- <50 years 3 324 999 30.0 (9.69–93.1) 6 338 1446 41.1 (18.6–92.4)
- ≥50 years 0 1469 4519 0 0 1577 6502 0
(p =0.002) (p < 0.001)
Treatment
-Tumorectomy 2 1325 4146 4.82 (1.21–19.3) 2 515 1972 20.3 (7.61–54.0)
-Mastectomy 1 468 1372 7.29 (1.03–51.7) 4 1400 5975 3.34 (0.84–13.4)
(p =0.73) (p = 0.018)
Histological grade
- G1 0 528 1515 0 0 564 2323 0
- G2 0 854 2770 0 2 908 3799 5.26 (1.32–21.0)
- G3 3 403 1211 24.8 (7.99–76.8) 4 435 1794 22.3 (8.4–59.4)
(p < 0.001) (p = 0.007)
Tumor size
- ≤ 15 mm 0 949 2927 0 0 1019 4280 0
- > 15 mm 3 838 2581 11.6 (3.75–36.0) 6 890 3649 16.4 (7.39–36.6)
(p = 0.07) (p = 0.008)
Vascular invasion
- No 1 1204 3779 2.64 (0.37–18.8) 1 1271 5323 1.88 (0.26–13.3)
- Yes 2 574 1697 11.8 (2.95–47.1) 5 626 2558 19.5 (8.13–47.0)
(p = 0.18) (p = 0.008)
pT stage
- pT1 1 1262 3945 2.53 (0.36–18.0) 1 1342 5683 1.76 (0.25–12.5)
- pT2 2 461 1394 14.3 (3.59–57.4) 5 493 1984 25.2 (10.5–60.5)
- pT3-4 0 66 172 0 0 76 269 0
(p = 0.30) (p = 0.01)
pN stage
- Negative (including ITC/
micrometastasis)/pN0
1 1273 3981 2.51 (0.35–17.8) 1 1335 5594 1.79 (0.25–12.7)
- from 1 to 3 positive/pN1 1 319 1006 9.94 (1.40–70.6) 2 338 1452 13.8 (3.44–55.1)
- >3 positives/pN2-pN3 1 149 391 25.6 (3.61–182) 3 167 604 49.7 (16.0–154)
(p = 0.26) (p = 0.004)
ER status
- Negative 2 181 532 37.6 (9.40–150) 3 190 776 38.6 (12.5–119)
- Positive 1 1581 4869 2.05 (0.89–14.6) 3 1693 7015 4.28 (1.38–13.3)
(p = 0.001) (p = 0.001)
PR status
- Negative 2 231 653 15.3 (2.16–109) 2 256 966 10.4 (1.46–73.5)
- Positive 1 1270 4090 4.89 (1.22–19.6) 3 1365 5496 7.28 (2.73–19.4)
(p = 0.054) (p = 0.19)
Ki67
- <20 % 0 1041 3224 0 2 1103 4600 4.35 (1.09–17.4)
Mittica et al. BMC Cancer  (2015) 15:1021 Page 5 of 8
analysis; in the latter analyses, the higher pT, more than
three metastatic lymph nodes and presence of vascular
invasion were also associated with an increased risk of
MC (Table 2, column B).
Finally, it appears that the rate of MC was higher in
the subgroup of patients with bone and/or brain metas-
tases (Table 3).
Discussion
MC diagnosis has increased in recent years due to
advances in imaging technology and the development of
new chemotherapy and immunotherapy approaches that
have improved the survival of patients with BC. Despite
the observed increase in clinical practice [27, 33], our re-
sults suggest that the incidence of MC remains low,
when considering an unselected population undergoing
surgery for BC. To date, few studies have analyzed the
occurrence of MC in patients with BC, and the results
vary depending on the study approach used. Briefly, in
advanced stages and autopsy series, MC incidence was
observed with rates ranging from 2.6 to 16 % [9, 11–14].
In a retrospective study based on a selected subgroup of
BC patients with metastatic disease, Yap et al. reported a
5 % incidence [6]. More recently, in a series of BC with
HER2 overexpression, MC incidence was observed in up
to 6.6 % of cases [8]. However, these relevant percent-
ages need to be critically interpreted because they have
been observed in selected high-risk categories of patients
with BC. The question then arises, what is the incidence
of MC in an unselected population with BC? To address
this issue, we decided to apply a rigorous definition of
our BC cohort to avoid selection bias. In fact, we in-
cluded all patients with BC who were consecutively
treated in our Breast Unit, not only those with meta-
static/advanced disease or with high-risk parameters. In
addition, we first restricted the main analyses to patients
who were expected to attend with high compliance dur-
ing the periodic follow up; that is, the large subgroup of
patients who regularly attended scheduled visits (ap-
proximately every 6 months) in the first 5 years after BC
diagnosis and surgery, regardless to disease stage.
In this well-defined cohort, 3 patients developed MC,
with a rate of incidence of 5.44 per 10,000 per year and
a 5-year risk of 0.3 %. Because some studies have re-
ported that the incidence of MC is most common in
patients with BC after 10 years from diagnosis [15, 34],
we also conducted an additional 10-year follow up ana-
lysis. During this period, we registered 3 additional cases
Table 2 Rate of breast cancer-related meningeal carcinomatosis, 5 years (column A) and 10 years (column B) after surgery
(Continued)
- ≥20 % 3 685 2037 14.7 (4.75–45.7) 4 741 2990 13.4 (5.02–35.6)
(p = 0.03) (p = 0.17)
HER2
- Negative 1 1574 4875 2.05 (0.29–14.6) 3 1662 6867 4.37 (1.41–13.5)
- Positive 2 144 452 44.2 (11.01–177) 3 151 632 47.5 (15.3–147)
(p < 0.001) (p < 0.001)
ITC isolated tumor cells
amissing data: Grading: 8 missing; pN stage: 52 missing; tumor size: 6 missing; ER: 31 missing; PR: 292 missing; Ki67: 67 missing; Vascular invasion: 15 missing; pT
stage: 4 missing; HER2: 75 missing
bmissing data: Grading: 8 missing; pN stage: 75 missing; tumor size: 6 missing; ER: 32 missing; PR: 294 missing; Ki67: 71 missing; Vascular invasion: 18 missing; pT
stage: 4 missing; HER2: 101 missing
Table 3 Rate of breast cancer related to meningeal carcinomatosis in patients with bone and/or brain metastasis occurrence:
5 years (column A) and 10 years (column B) after surgery
Column A: 5-year follow up Column B: 10-year follow up
MC events Patients Person-years Rate (per 100) MC events Patients Person-years Rate (per 100)
Occurrence of bone metastasisa
No 2 1780 5434 0.037 (0.0092–0.147) 3 1898 7770 0.039 (0.012–0.12)
Yes 1 52 84 1.19 (0.168–0.85) 3 87 177 1.69 (0.55–5.25)
(p < 0.001) (p < 0.001)
Occurrence of brain metastasis
No 2 1792 5510 0.036 (0.0091–0.15) 3 1912 7929 0.038 (0.012–0.12)
yes 1 9 7 14.36 (2.02–101.93) 3 15 18 16.58 (5.35–51.41)
(p < 0.001) (p < 0.001)
aPatients sum up to more than 1793 (5-year follow-up) or 1915 (10-year follow-up) because bone and brain metastases are time-dependent variables; thus, a
single patient who developed metastasis during the follow up contributed to both levels (yes and no) of the variable
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of MC, which determined a non-substantial increase in
the rate of MC incidence. Overall, in our consecutive
and unselected population of patients with BC who were
treated and followed in the same Breast Unit, the 5- and
10-year risk rates of MC development were lower than
1 %. Similarly, brain metastases occurred in 0.9 % of the
cohort (and 83 % of MC exhibited an associated brain
lesion). These results appear similar to those reported
two decades ago by Jayson et al., who described a 0.86 %
incidence rate of MC in an unselected series of patients
with BC [7]. In the same study, focusing on a subgroup
of patients treated for recurrent disease, an increased
incidence of up to approximately 2 % was observed [7].
To our knowledge, this was the only study to examine
the unbiased incidence rate of MC in BC, and the
consistency of the results with our data obtained 20
years later leads to two hypotheses: either the “real” inci-
dence of MC in an unselected BC population has under-
gone an apparent, but not true increase, or the “real”
incidence remains underestimated.
Considering that patients with BC and neurological
symptoms may be referred to the emergency room or to
a neurological setting (where MC is usually managed),
we can hypothesize that the source of the data (Breast
Unit medical charts) might represent a limitation.
As a second step, we attempted to solve the important
and partially unmet need to identify patients with BC
who are at high risk for MC development; to this end,
we searched for clinico-pathological and molecular fea-
tures that might be useful as possible predictors of in-
creased MC risk. We observed that established
predictors of worse prognosis (young age, tumor size ex-
ceeding 15 mm, high histological grade, more than three
metastatic lymph nodes, ER-negative and HER2-positive
status and high proliferative index) were associated with
an increased risk of MC, in agreement with other studies
[25, 27, 35–39].
Conclusions
MC remains a rare condition with a usual occurrence in
the natural history of BC. Late diagnosis of MC leads pa-
tients to non-eligibility for standard therapeutic strat-
egies, including radiotherapy and intrathecal and/or
systemic chemotherapy and to the delivery of palliative
care. Consequently, the identification of a clinico-
pathological profile of patients with BC who are at in-
creased MC risk would be useful so that they might be
directed to a strict follow up aimed at anticipating MC
diagnosis prior to symptom presentation, as also sug-
gested by a recent review of clinical trials [40]. However,
the low incidence of MC and the lack of specific risk
factors make it difficult to generate a dedicated diagnos-
tic screening work up that is designed to precociously
detect MC in patients with BC.
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